Responses
Regular and young investigator award abstracts
Checkpoint blockade therapy
203 Preclinical characterization and development of MG1124, a Novel Immune Checkpoint inhibitor targeting CEACAM1 for NSCLC patients
Compose a Response to This Article
Other responses
No responses have been published for this article.
